TDC
KDNY

Thompson Davis & Co’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Thompson Davis & Co’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200
Closed -$11K – 1260
2016
Q4 		$11K Hold
200
– – 0.02% 686
2016
Q3 		$12K Hold
200
– – 0.02% 630
2016
Q2 		$11K Buy
+200
New +$12.2K 0.02% 624

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Thompson Davis & Co's KDNY Position: Q1 2017 in Review

Thompson Davis & Co sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2017, closing a stake of 200 shares — an estimated $11K sold.

Thompson Davis & Co first reported a position in KDNY in Q2 2016 and held it in 3 quarters. The position peaked at $12K in Q3 2016. 82 funds tracked by Wall St. Rank hold KDNY as of Q1 2017.

  • Thompson Davis & Co reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 200 Chinook Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $11K.
  • Thompson Davis & Co first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • Thompson Davis & Co's Chinook Therapeutics, Inc. Common Stock position peaked at $12K in Q3 2016.
  • 82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Thompson Davis & Co's 13F filing for Q1 2017, filed 8 May 2017.